Fractyl Health, Inc. GUTS
Medical/Dental Instruments · IPO 2024 · data as of November 13, 2026
Fractyl Health, Inc. (GUTS) is a healthcare company listed in the US with a market value of about $12M.
Its overall Stock Analiz score is 0.0 out of 5 (weak). The strongest part is value (0/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -94%.
About Fractyl Health
Fractyl Health is listed in the US and classified in medical/dental instruments, IPO year 2024. It was profitable in 0 of the last 3 years in our data.
Score: 0.0 / 5
Checks passed
- —
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $0 | $93000 | $120000 |
| Net income | -$141M | -$69M | -$77M |
| Free cash flow | -$91M | -$67M | -$43M |
| EPS (diluted) | $-11.16 | $-9.72 | $-271.74 |
| Net margin | — | -73864.5% | -64242.5% |
| ROIC | -107.6% | -81.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $23.80, 2534% above the current price; targets range from $4.00 to $46.00; the consensus rating is “Strong buy”; expected EPS is $-3.39 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Fractyl Health pay a dividend?
Not currently.
Is Fractyl Health a good stock to buy?
We do not give buy or sell advice. Fractyl Health scores 0.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.